KALV Stock Summary and Trading Ideas (Kalvista Pharmaceuticals | NASDAQ:KALV)

KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.

What symbol and exchange does Kalvista Pharmaceuticals shares trade?

Kalvista Pharmaceuticals trades on the NASDAQ stock market under the symbol KALV.

What is Kalvista Pharmaceuticals stock price doing today?

As of June 3, 2026, KALV stock price climbed to $26.95 with 6,281,840 million shares trading.

What is Kalvista Pharmaceuticals's Beta?

KALV has a beta of 0.35, meaning it tends to be less sensitive to market movements. KALV has a correlation of 0.00 to the broad based SPY ETF.

How much is Kalvista Pharmaceuticals worth?

KALV has a market cap of $1.43 billion. This is considered a Small Cap stock.

How much money does Kalvista Pharmaceuticals make?

Last quarter Kalvista Pharmaceuticals reported $41 million in Revenue and -$.43 earnings per share. This beat revenue expectation by $2 million and missed earnings estimates by -$.05.

What is the highest and lowest price Kalvista Pharmaceuticals traded in the last 3 year period?

In the last 3 years, KALV traded as high as $26.98 and as low as $7.21.

What are the top ETFs holding Kalvista Pharmaceuticals?

The top ETF exchange traded funds that KALV belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

Is Kalvista Pharmaceuticals (KALV) a good investment?

KALV has outperformed the market in the last year with a return of +108.6%, while the SPY ETF gained +28.5%. In the last 3 month period, KALV beat the market returning +67.8%, while SPY returned +10.1%. However, in the most recent 2 weeks KALV has underperformed the stock market by returning +0.7%, while SPY returned +2.8%.

What are the support and resistance levels for Kalvista Pharmaceuticals (KALV)?

KALV support price is $26.89 and resistance is $26.99 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KALV shares will trade within this expected range on the day.